Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PMI vs NPCE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PMI Captures Overall Composite Edge (48.4 HOLD vs 48.8 HOLD), While NPCE Leads 4–1 on Growth & Valuation Pillars
PMI Overall Winner
6-Pillar Tally: PMI 1 – 4 NPCE (1 Tie)
Matrix Metrics: PMI 6 – 4 NPCE
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Neuropace, Inc. (NPCE) on higher Unified Composite conviction (48.4/100 HOLD vs. 48.8/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while NPCE wins 4–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus NPCE at $8.14 (90.9x Forward P/E, -9.6% operating margin).
- Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. NPCE 48.8/100 HOLD) and 54.06β · 134% Vol risk profile, whereas NPCE leads top-line expansion (-1.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PMI vs NPCE
PMI
Head-to-Head Winner
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
NPCE
Neuropace, Inc. Common Stock
$8.14
-0.97% 1D
Market Cap
$283.2M
TTM Revenue
$107M
Forward P/E
90.9x
Beta / 30D Vol
1.22β · 136% Vol
Unified Composite Score
48.8
HOLD
Tech 60.0
Fund 60.0
Flow 71.0
Mom 48.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 4 NPCE)
1. Valuation Multiples
NPCE
Forward P/E
N/M
90.9x
Trailing P/E
2.9x
90.9x
PEG Ratio
N/M
N/M
EV / Revenue
3.2x
3.2x
2. Growth & Scale
NPCE
Revenue Growth (YoY)
+38.6%
-1.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$6.3M
$107M
Market Cap
$17.1M
$283.2M
3. Profitability & Quality
NPCE
Gross Margin
18.6%
77.8%
Operating Margin
-248.1%
-9.6%
Net Profit Margin
0.0%
-17.7%
Return on Equity (ROE)
0.0%
-97.0%
4. Balance Sheet & Cash Flow
NPCE
Cash Generation (TTM)
-$17M
-$12M
Cash Flow Margin
N/A
-10.9%
Net Cash / Leverage
$3.2M Net Debt
$57M Net Debt (5.88x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PMI
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
59.9% (10th %ile)
Put/Call OI Skew
N/A
0.34x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PMI (6) vs NPCE (4)| Institutional Metric | PMI | NPCE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.1M | $283.2M | NPCE | |
| Trailing P/E Ratio | 2.9x | 90.9x | PMI | |
| Forward P/E Ratio | N/M | 90.9x | NPCE | |
| Revenue Growth (YoY) | +38.6% | -1.1% | PMI | |
| Operating Margin (TTM) | -248.1% | -9.6% | NPCE | |
| Net Profit Margin | 0.0% | -17.7% | PMI | |
| Return on Equity (ROE) | 0.0% | -97.0% | PMI | |
| 52-Week Range Position | 34% ($0–$18) | 19% ($5–$20) | PMI | |
| Beta / 30D Volatility | 54.06β · 134% Vol | 1.22β · 136% Vol | PMI | |
| Unified Institutional Score | 48.4 / 100 (HOLD) | 48.8 / 100 (HOLD) | NPCE | |
| Trailing 12M Revenue (USD) | $6.3M | $107M | Scale | |
| Gross Profit Margin (TTM) | 18.6% | 77.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.2x EV/Rev | N/M PEG · 3.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($3.2M Net Debt) | -$12M ($57M Net Debt (5.88x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PMI +3.04 pp
3M Horizon
PMI +138.24 pp
6M Horizon
PMI +3487.81 pp
1Y Horizon
PMI +185.51 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PMI Revenue | NPCE Revenue | PMI Op. Margin | NPCE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $40M | N/A | -31.7% | NPCE |
| FY2021 | N/A | $50M | N/A | -52.5% | NPCE |
| FY2022 | N/A | $50M | N/A | -89.6% | NPCE |
| FY2023 | N/A | $70M | N/A | -41.5% | NPCE |
| FY2024 | $0M | $80M | -312.3% | -27.1% | NPCE |
| FY2025 | $0M | $100M | -268.4% | -16.3% | NPCE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NPCE
BREAKDOWN
Current IV
59.9%
IV Percentile
10th %ile
Put/Call OI Skew
0.34x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NPCE Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PMI vs NPCE Key Questions & Quantitative Answers
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Neuropace, Inc. (NPCE) on higher Unified Composite conviction (48.4/100 HOLD vs. 48.8/100 HOLD) after splitting the core matrix 6–4 (led by Options & Positioning), while NPCE wins 4–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus NPCE at $8.14 (90.9x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. NPCE 48.8/100 HOLD) and 54.06β · 134% Vol risk profile, whereas NPCE leads top-line expansion (-1.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NPCE leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with NPCE at -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), PMI cumulative revenue shifted N/A while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.
NPCE screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas NPCE trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-10.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus NPCE (-97.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 136% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NPCE vs PMI · Reverse Pair
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
PMI vs MBI
· Sector Peer
NPCE vs TMCI
· Sector Peer
NPCE vs SGHT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem